# Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

> **NCT05919108** · PHASE2 · RECRUITING · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 30 (estimated)

## Conditions studied

- Anatomic Stage I Breast Cancer
- Anatomic Stage II Breast Cancer
- Anatomic Stage III Breast Cancer
- Invasive Breast Lobular Carcinoma

## Interventions

- **PROCEDURE:** Endocrine Therapy
- **PROCEDURE:** Biopsy of breast
- **DRUG:** Neratinib
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Mammogram
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Breast Surgery
- **PROCEDURE:** Ultrasound

## Key facts

- **NCT ID:** NCT05919108
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-30
- **Primary completion:** 2030-04-30
- **Final completion:** 2031-04-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-09-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05919108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05919108, "Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05919108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*